Lexeo Therapeutics (LXEO) Retained Earnings (2022 - 2026)

Lexeo Therapeutics has reported Retained Earnings for 5 years, with the latest figure at -$400.3 million in Q1 2026.

• Quarterly Retained Earnings fell 741251.85% year-over-year to -$400.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$400.3 million (down 741251.85% YoY) and the FY2025 annual result came in at -$380.1 million, down 368962.14% from the prior year.
• Retained Earnings fell to -$400.3 million in Q1 2026 per LXEO's latest filing, from -$380.1 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$13000.0 in Q2 2025 and troughed at -$400.3 million in Q1 2026.
• A 5-year average of -$192.4 million and a median of -$203.3 million in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings jumped 99.99% in 2025, then plunged 741251.85% in 2026.
• Over 5 years, Retained Earnings stood at -$115.4 million in 2022, then tumbled by 57.51% to -$181.8 million in 2023, then surged by 99.94% to -$103000.0 in 2024, then sank by 368962.14% to -$380.1 million in 2025, then slipped by 5.31% to -$400.3 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$400.3 million, -$380.1 million, and -$359.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.